Therapeutic | Caplacizumab |
Target | VWF |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGRTFSYNPMGWFRQAPGKGRELVAAISRTGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAAGVRAEDGRVRTLPSEYTFWGQGTQVTVSS |
Light Chain | na |
100% seqID Fv Structure | 7a6o [Fvs: B], 7eow [Fvs: B] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 7a6o [Fvs: B] |
100% seqID Structure | 7eow [Fvs: B] |
Follow these links to our prediction tools:
Format | Nanobody |
Isotype | na |
Highest Clinical Trial (January '23) | Approved |
Estimated Status (January '23) | NFD |
Recorded Developmental Technology | Nanobody Technology |
INN Year Proposed | 2011 |
INN Year Recommended | 2012 |
Companies Involved | Ablynx |
Conditions Approved | Thrombotic thrombocytopenic purpura |
Conditions Active | na |
Conditions Discontinued | Thrombosis |
Notes |
SAbDab papers
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]
Thera-SAbDab paper
Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]